{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=52", "query": { "condition": "Pharmacokinetics and Pharmacodynamics", "page": 52 }, "page_size": 10 }, "pagination": { "page": 52, "page_size": 10, "total_count": 2341, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=53&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=51&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T22:54:04.899Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04224493", "title": "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Follicular Lymphoma", "Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" }, { "name": "Lenalidomide", "type": "COMBINATION_PRODUCT" }, { "name": "Rituximab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 599, "start_date": "2020-06-11", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 57, "location_summary": "Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04224493" }, { "nct_id": "NCT05843578", "title": "STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrostenotic Crohn's Disease" ], "interventions": [ { "name": "AGMB-129", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agomab Spain S.L.U.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2023-08-01", "completion_date": "2026-06-20", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 11, "location_summary": "Hamden, Connecticut • Miami, Florida • Orlando, Florida + 8 more", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "New Albany", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05843578" }, { "nct_id": "NCT01831804", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Wound Healing" ], "interventions": [ { "name": "GSK1278863", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 65, "start_date": "2013-06-17", "completion_date": "2017-02-10", "has_results": true, "last_update_posted_date": "2019-08-19", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 7, "location_summary": "Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more", "locations": [ { "city": "Castro Valley", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Pinellas Park", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831804" }, { "nct_id": "NCT01475006", "title": "AMG 595 First-in-Human in Recurrent Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Glioma", "Anaplastic Astrocytomas", "Glioblastoma Multiforme" ], "interventions": [ { "name": "AMG 595", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2012-02", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-04-15", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 3, "location_summary": "Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475006" }, { "nct_id": "NCT04504448", "title": "A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "HNC664 capsules Single dose", "type": "DRUG" }, { "name": "HNC664 placebos Single dose", "type": "DRUG" }, { "name": "HNC664 capsules FED", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guangzhou Henovcom Bioscience Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 45, "start_date": "2020-08-11", "completion_date": "2021-07-13", "has_results": false, "last_update_posted_date": "2022-08-26", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504448" }, { "nct_id": "NCT01884285", "title": "AZD8186 First Time In Patient Ascending Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Castrate-resistant Prostate Cancer CRPC", "Squamous Non-Small Cell Lung Cancer sqNSCLC", "Triple Negative Breast Cancer TNBC" ], "interventions": [ { "name": "Part A: AZD8186 monotherapy", "type": "DRUG" }, { "name": "Part B: AZD8186 monotherapy", "type": "DRUG" }, { "name": "Part C1: Abiraterone acetate combination with AZD8186", "type": "DRUG" }, { "name": "Part D1: AZD2014 combination with AZD8186", "type": "DRUG" }, { "name": "Part D2 AZD2014 combination with AZD8186", "type": "DRUG" }, { "name": "Part C2: Abiraterone acetate combination with AZD8186", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 147, "start_date": "2013-07-09", "completion_date": "2020-02-07", "has_results": false, "last_update_posted_date": "2020-05-29", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01884285" }, { "nct_id": "NCT01284062", "title": "Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Anrukinzumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 84, "start_date": "2011-03", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-11-18", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01284062" }, { "nct_id": "NCT02588950", "title": "A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "U-500R", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 11, "start_date": "2016-01-12", "completion_date": "2017-05-25", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588950" }, { "nct_id": "NCT05734196", "title": "The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency", "Autosomal Recessive Hypophosphatemic Rickets", "Generalized Arterial Calcification of Infancy", "ATP-Binding Cassette Subfamily C Member 6 Deficiency", "Pseudoxanthoma Elasticum" ], "interventions": [ { "name": "INZ-701", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inozyme Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "1 Year", "sex": "ALL", "summary": "Up to 1 Year" }, "enrollment_count": 9, "start_date": "2023-06-25", "completion_date": "2026-09-29", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 3, "location_summary": "San Diego, California • Columbus, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05734196" }, { "nct_id": "NCT06310291", "title": "VTP-1000 in Adults With Celiac Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Celiac Disease" ], "interventions": [ { "name": "VTP-1000", "type": "BIOLOGICAL" }, { "name": "Matched Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Barinthus Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 45, "start_date": "2024-08-01", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-20T22:54:04.899Z", "location_count": 16, "location_summary": "Los Angeles, California • Colorado Springs, Colorado • Jacksonville, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06310291" } ] }